NCT04958785 2025-11-04
ELEVATE TNBC
Gilead Sciences
Phase 2 Terminated
Clinical Trials
34 trialsNCT04216472 2025-09-30
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03655080 2025-02-04
Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression
Washington University School of Medicine
Phase 2 Terminated
NCT02887248 2023-12-05
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT02710396 2023-07-24
Genetic Predictors of Benefit to Pembrolizumab
Columbia University
Phase 2 Terminated
NCT01147016 2023-04-27
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT02229149 2022-12-02
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
US Oncology Research
Phase 2 Terminated
NCT01779050 2022-11-01
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Washington University School of Medicine
Phase 2 Terminated
NCT02967133 2022-09-08
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Alliance Foundation Trials, LLC.
Phase 2 Terminated
NCT01461915 2022-06-06
PGPC1
Jazz Pharmaceuticals
Phase 2 Terminated
NCT02183805 2021-07-23
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer
Sun Yat-sen University
Phase 2 Terminated
NCT00622466 2020-10-19
Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT00281528 2019-11-22
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Celgene
Phase 2 Terminated
NCT02598310 2019-08-28
Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer
Osaka Medical College
Phase 2 Terminated
NCT02124369 2019-07-16
PRICKLE
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT01376310 2019-02-19
GSK1120212 Rollover Study
Novartis
Phase 2 Terminated
NCT01372202 2019-01-25
J10130
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT02109445 2019-01-10
Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies
Pfizer
Phase 2 Terminated
NCT02241551 2018-07-26
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
University of Pittsburgh
Phase 2 Terminated
NCT01921751 2018-07-13
High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Radiation Therapy Oncology Group
Phase 2 Terminated
NCT01851174 2018-02-07
Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer
Western Regional Medical Center
Phase 2 Terminated
NCT00319839 2018-01-12
Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab
University of California, Irvine
Phase 2 Terminated
NCT00585052 2018-01-05
A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
University of Iowa
Phase 2 Terminated
NCT02076243 2017-10-25
Treatment With Nab-paclitaxel in Cutaneous SCC
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT00454324 2017-07-11
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT02276560 2017-05-11
LCCC1407
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT02242409 2017-02-14
Study of Gemcitabine and Abraxane for Pancreas Cancer
Georgetown University
Phase 2 Terminated
NCT01980810 2016-06-14
GC-A-003
ChineseAMS
Phase 2 Terminated
NCT00521781 2016-03-17
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT00995488 2015-09-11
Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT01207102 2014-12-15
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
Duke University
Phase 2 Terminated
NCT01821859 2013-07-26
Abraxane/Bevacizumab
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01416558 2013-05-22
Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)
GBG Forschungs GmbH
Phase 2 Terminated
NCT00607438 2012-05-11
A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer
Veeda Oncology
Phase 2 Terminated